NovaBridge reports phase 1b data for gastric cancer drug
NovaBridge Biosciences (NASDAQ: NBP) presented Phase 1b data for givastomig in gastric cancer treatment at ESMO 2026. The 8 mg/kg dose showed 79% objective response rate and 16.9 months median progression-free survival. The company plans registrational development and has FDA alignment. Givastomig has Orphan and Fast Track designations.
How this was made
The 30-second read
Why it matters
The data shows high response and disease control rates, earning FDA orphan and fast‑track designations, which could lift the stock.
Market read
First disclosure of promising trial data for a biotech company, likely to affect its share price.
What to watch
Long-term safety and regulatory timelines remain uncertain.
Background
NovaBridge Biosciences (NASDAQ:NBP) presented updated Phase 1b results for its bispecific antibody givastomig at the ESMO Congress.
Ticker impact
NovaBridge reported Phase 1b data with 79% response rate and FDA designations, a first disclosure of trial results.
potential upside as investors price in robust response and disease control rates
First-time release of compelling Phase 1b data typically moves biotech stocks.
Market effects
Positive data may boost confidence in CLDN18.2‑targeted therapies across the oncology sector.
US biotech market could see modest gains from the news.
Limited to oncology biotech investors.
Counterpoint
If later-stage data fails to confirm efficacy, early enthusiasm could reverse.
Key entities
- companyNovaBridge Biosciences
Biotech firm developing givastomig.
- regulatorFDA
Granted orphan drug and fast‑track designations.
